Alder Biopharmaceuticals, Inc. [NASDAQ:ALDR]: Analyst Rating and Earnings
Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Alder Biopharmaceuticals, Inc. [ALDR] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give ALDR an Outperform rating. The average 12-month price forecast for this stock is $22.13, with the high estimate being $36.00, the low estimate being $9.00 and the median estimate amounting to $22.00. This is compared to its latest closing price of $10.77.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Alder Biopharmaceuticals, Inc. [ALDR] is sitting at 2.31. This is compared to 1 month ago, when its average rating was 2.31.
Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Mon 25 Feb (In 43 Days).
Fundamental Analysis of Alder Biopharmaceuticals, Inc. [ALDR]
Now let’s turn to look at profitability: with a current Operating Margin for Alder Biopharmaceuticals, Inc. [ALDR] sitting at -17974.31 and its Gross Margin at -185.36. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -87.91, and its Return on Invested Capital has reached -104.20%. Its Return on Equity is -87.27, and its Return on Assets is -81.11. These metrics suggest that this Alder Biopharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -1.83. The Enterprise Value to Sales for this firm is now 564.07. Alder Biopharmaceuticals, Inc. [ALDR] has a Price to Book Ratio of 2.78.
Shifting the focus to workforce efficiency, Alder Biopharmaceuticals, Inc. [ALDR] earns $8,389 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.00. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 12.29 and its Current Ratio is 12.29. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Alder Biopharmaceuticals, Inc. [ALDR] has 63.39M shares outstanding, amounting to a total market cap of $686.51M. Its stock price has been found in the range of 9.44 to 20.87. At its current price, it has moved by -48.10% from its 52-week high, and it has moved 14.72% from its 52-week low.
This stock’s Beta value is currently 2.63, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 45.95. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Alder Biopharmaceuticals, Inc. [ALDR] a Reliable Buy?
Alder Biopharmaceuticals, Inc. [ALDR] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.